Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
Sponsor: Alnylam Pharmaceuticals
A observational or N/A phase clinical study on Chronic Hepatitis B, this trial is completed. The trial is conducted by Alnylam Pharmaceuticals and has accumulated 14 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Apr 17, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Sep 2025 — Apr 2026 [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Contact Information
- Alnylam Pharmaceuticals
- Vir Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Auckland, New Zealand , Bangkok, Thailand , Bangkok, Thailand , Bangkok, Thailand , Batu Caves, Malaysia , Birtinya, Australia , Busan, South Korea , Chiang Mai, Thailand , Chuncheon, South Korea and 12 more locations